statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results PR...

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host...

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

Relmada Therapeutics, Inc. (NASDAQ:RLMD  Free Report)  Equities research analysts at Leerink Partnrs issued their Q1 2024 EPS estimates for shares of Relmada Therapeutics in a...

Leerink Partnrs Comments on Relmada Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:RLMD)

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop...

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

This price move could indicate a change in the trend, and may be a sell signal for investors...

Relmada Therapeutics (RLMD, $4.44) price exceeded its 50-day Moving Average on March 20, 2024

Progress in CNS Treatments Amid Financial ChallengesRelated Stocks: RLMD...

Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year...

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024 Relmada Therapeutics to Report Fourth Quarter and Full-Year...

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024

This indicator may be signaling that RLMD's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Relmada Therapeutics (RLMD, $5.77) entered Downtrend as Momentum indicator drops below 0 level on Mar 11, 2024

This is a Bearish indicator signaling RLMD's price could decline from here. Traders may explore shorting the stock or put options...

Relmada Therapeutics (RLMD, $6.37) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 7, 2024

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Watchers	1,399
52-Wk Low	$2.36
52-Wk High	$7.22

Volume	46,958.00
52-Wk High	$7.22
52-Wk Low	$2.36

RLMD Relmada Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community